Drugs & TargetsFree Poseida, Roche to collaborate on allogeneic CAR T-cell therapies for hematologic malignancies August 05, 2022Vol.48 No.31
Drugs & Targets FDA accepts ImmunityBio’s BLA for bladder cancer therapy N-803 July 29, 2022Vol.48 No.30
Drugs & Targets Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate July 29, 2022Vol.48 No.30
Drugs & Targets Mission Bio establishes early access program for single-cell measurable residual disease detection in blood cancers July 29, 2022Vol.48 No.30
Drugs & Targets FDA grants eltanexor with fast track designation; EU Commission designates eltanexor as an orphan medicinal product July 22, 2022Vol.48 No.29
Drugs & Targets FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor July 15, 2022Vol.48 No.28
Drugs & Targets FDA accepts BLA for mosunetuzumab in relapsed or refractory follicular lymphoma July 08, 2022Vol.48 No.27
Drugs & Targets AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486 July 08, 2022Vol.48 No.27
Drugs & TargetsFree FDA approves Breyanzi in relapsed or refractory large B-cell lymphoma after one prior therapy July 01, 2022Vol.48 No.26
Drugs & TargetsFree EMA CHMP adopts positive opinion for Lynparza in germline BRCA-mutated, HER2-negative high-risk early breast cancer July 01, 2022Vol.48 No.26
